Half Year 2026 CogState Ltd Earnings Call Transcript
Key Points
- Cogstate Ltd (COGZF) reported a 105% increase in sales contracts for the December half-year, totaling $41.7 million.
- The company managed a portfolio of 133 clinical trials, marking a 34% increase from the previous year.
- Cogstate Ltd (COGZF) expanded its customer base by adding new pharma and larger biotech customers, enhancing potential for multi-program trials.
- The company's channel partnership program has been a significant growth driver, contributing to 70% of sales opportunities and 62% of executed sales contracts.
- Cogstate Ltd (COGZF) has a strong cash position with $34.1 million on hand and no debt, supporting its investment in technology and growth initiatives.
- Revenue for the first half was $26.9 million, slightly below expectations due to lower in-period revenue yield.
- Gross profit decreased by 3% year-to-year, with margins down by 8.6% due to increased investment in resources.
- The company faced a provision for doubtful debt of $500,000 related to an unsuccessful study with a US biotech.
- License fee revenue, which was 23% of clinical trials revenue, was down from 31% in the most recent June half.
- Cogstate Ltd (COGZF) did not declare an interim dividend for the half-year, maintaining a cautious approach to capital allocation.
Good morning everyone. Welcome to CogState's full year results for financial year '25. I'm pleased to introduce on our call today, Brad OâConnor CEO and Managing Director, Darren Watson, our CFO, and Rachel Colite, our executive VP of clinical trials. Before we get started, a reminder that this webinar is being recorded. (Operator Instructions)
I'd like to now hand over to you, Brad.
Thanks,welcome everybody and thank you for joining us today. We're really excited to bring you, these results. We'll dig into the dig into the numbers, but I think what's really interesting is that within Cogstate, we feel that the business is changing, fairly substantially, over the last six months and through today's presentation, we're going to try and draw out those changes and the growth that we're seeing in the business, as well as the financial results.
So, today's presentation, of course, includes forward-looking statements and therefore I note our disclaimer stating that this
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
